Clinical trials: Locally Advanced Pancreas Cancer
Pancreatic Cancer
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00601627
- Testing
- panitumumab, capecitabine, fluorouracil
- Where
- 281 sites in United States
- Volunteers
- 52 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
A multi-institutional, single arm phase II study of nivolumab, cabiralizumab and stereotactic body radiotherapy (SBRT) in patients with LAUPC.
- Trial name
- NCT03599362
- Testing
- Nivolumab + Cabiralizumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- NYU Langone Health
Pancreatic Cancer
Chemoradiation in Locally Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00262951
- Testing
- recombinant interferon alfa, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Pancreatic Cancer
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreatic cancer (LAPC). Secondary Endpoints: 1.
- Trial name
- NCT00831493
- Testing
- Chemoradiation (Radiation Therapy), Vorinostat
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreas Cancer
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Patients are being asked to participate in this study who have locally advanced or metastatic pancreatic cancer (cancer of the pancreas that has spread to another part of the body) that has gotten worse after first-line…
- Trial name
- NCT00881621
- Testing
- Lapatinib and Capecitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Georgetown University
Histologically or Cytologically Confirmed Pancreatic Ca, Unresectable or Borderline Resectable Pancreatic Ca
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Background: Pancreatic cancer is difficult to treat because by the time most cases are diagnosed, the tumors are too large to be removed surgically.
- Trial name
- NCT01294358
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer Non-resectable
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the…
- Trial name
- LAPIS (NCT03941093)
- Testing
- Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
- Where
- 90 sites in United States, Austria and 10 more
- Volunteers
- 284 people
- Sponsor
- Kyntra Bio
Pancreatic Cancer
Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer
This is a Phase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether the combination of drugs works in treating a specific cancer.
- Trial name
- NCT01821729
- Testing
- FOLFIRINOX, Losartan, Proton Beam Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Locally Advanced or Metastatic Solid Tumours
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT04999969
- Testing
- AZD0171, Durvalumab, Gemcitabine
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
This 2 part study will evaluate the safety and efficacy of a combination of Avastin, Tarceva and Xeloda (ATX) as second-line treatment in patients with locally advanced and/or metastatic pancreatic cancer.
- Trial name
- NCT00925769
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], erlotinib [Tarceva]
- Where
- 2 sites in Austria
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared to gemcitabine in combination with placebo in subjects with locally advanced unresectable or metastatic…
- Trial name
- MAESTRO (NCT01746979)
- Testing
- TH-302, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 693 people
- Sponsor
- ImmunoGenesis
Pancreatic Cancer
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
This is a dose escalation trial to evaluate the safety of stereotactic body radiotherapy (SBRT) delivered in 3 fractions for patients with locally advanced pancreatic cancer (LAPC) who have received induction chemotherapy…
- Trial name
- NCT02873598
- Testing
- FOLFIRINOX or gemcitabine/abraxane, SBRT
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
Gastrointestinal Neoplasms, Ovarian Neoplasms
Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
The purposes of this study are: 1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy ) or WART(Whole Abdominal Radiation Therapy) given in combination with standard fixed dose-rate…
- Trial name
- GCC0319 (NCT00390182)
- Testing
- Gemcitabine
- Where
- 2 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- University of Maryland, Baltimore
Adenocarcinoma of the Pancreas, Pancreatic Cancer
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
This phase II trial is studying how well E7389 works as second-line therapy in treating patients with locally advanced, unresectable, or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer
- Trial name
- NCT00383760
- Testing
- eribulin mesylate
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
This phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is…
- Conditions
- Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8, Stage III Pancreatic Cancer American Joint Committee on Cancer v8
- Trial name
- NCT04539808
- Testing
- Capecitabine, Fluorouracil, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Cancer
Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00408564
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Medical University of South Carolina
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Pancreatic Cancer, Pancreatic Cancer
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10…
- Trial name
- NCT02578732
- Testing
- FOLFOXA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Brown University
Adenocarcinoma of the Pancreas, Locally Advanced
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
This study is a phase 2, multicenter, randomized, double-blind, active placebo-controlled trial of AMG 479 or placebo in combination with gemcitabine as first-line therapy for locally advanced unresectable adenocarinoma of the…
- Conditions
- Adenocarcinoma of the Pancreas, Locally Advanced, Unresectable
- Trial name
- NCT01318642
- Testing
- Gemcitabine, AMG 479
- Where
- 35 sites in United States, Austria and 11 more
- Volunteers
- 10 people
- Sponsor
- NantBioScience, Inc.